Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab ...
Akeso presented efficacy data for its PD-1/VEGF bispecific antibody, ivonescimab, with or without ligufalimab, combined with FOLFOXIRI as a first-line treatment for metastatic colorectal cancer at the 2024 ESMO Conference. Both regimens showed high anti-tumor activity and effective disease control for MSS/pMMR mCRC, with ivonescimab plus ligufalimab demonstrating superior efficacy.
Reference News
Akeso presented efficacy data for its PD-1/VEGF bispecific antibody, ivonescimab, with or without ligufalimab, combined with FOLFOXIRI as a first-line treatment for metastatic colorectal cancer at the 2024 ESMO Conference. Both regimens showed high anti-tumor activity and effective disease control for MSS/pMMR mCRC, with ivonescimab plus ligufalimab demonstrating superior efficacy.